SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 72 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $222,000 | -70.5% | 11,542 | -73.3% | 0.03% | -67.3% |
| Q1 2022 | $753,000 | +41.3% | 43,300 | +80.7% | 0.10% | +16.1% |
| Q4 2020 | $533,000 | -3.4% | 23,958 | -36.0% | 0.09% | -5.4% |
| Q3 2020 | $552,000 | +173.3% | 37,420 | +62.4% | 0.09% | +283.3% |
| Q4 2019 | $202,000 | -11.8% | 23,041 | -6.1% | 0.02% | -7.7% |
| Q2 2019 | $229,000 | +186.2% | 24,550 | +60.2% | 0.03% | +225.0% |
| Q1 2019 | $80,000 | -78.3% | 15,323 | -70.8% | 0.01% | -55.6% |
| Q2 2018 | $368,000 | – | 52,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |